ETS transcription factors in endocrine systems

Trends in Endocrinology and Metabolism

Volumn 18, Issue 4, 2007, Pages 150-158

  Gutierrez Hartmann, Arthur ^a   Duval, Dawn L ^a,b   Bradford, Andrew P ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; PROLACTIN; TRANSCRIPTION FACTOR ETS;

BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; HYPOPHYSIS FUNCTION; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MAMMARY GLANDS, HUMAN; MODELS, MOLECULAR; PANCREATIC NEOPLASMS; PITUITARY GLAND; PROSTATE; PROTO-ONCOGENE PROTEINS C-ETS; REPRODUCTION; THYROID NEOPLASMS;

EID: 34247369371     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2007.03.002     Document Type: Review

References (71)

1. Seth A., and Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41 (2005) 2462-2478
2. Sharrocks A.D. The ETS-domain transcription factor family. Nature 2 (2001) 827-837
3. Wasylyk B., et al. Ets transcription factors: nuclear effectors of the Ras/MAP kinase signaling pathway. Trends Biochem. Sci. 23 (1998) 213-216
4. Galang C.K., et al. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J. Biol. Chem. 279 (2004) 11281-11292
5. Hollenhorst P.C., et al. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 32 (2004) 5693-5702
6. Prescott J.D., et al. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol. Cell. Biol. 24 (2004) 5548-5564
7. Feldman R.J., et al. The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Res. 23 (2003) 2125-2131
8. Jorgensen J.S., et al. Multiple and overlapping combinatorial codes orchestrate hormonal responsiveness and dictate cell-specific expression of the genes encoding luteinizing hormone. Endocr. Rev. 25 (2004) 521-542
9. Duan W.R., et al. GnRH regulates early growth response protein 1 transcription through multiple promoter elements. Mol. Endocrinol. 16 (2002) 221-233
10. Liu J.C., et al. Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J. Biol. Chem. 277 (2002) 35819-35825
11. Gourdji D., and Laverriere J.-N. The rat prolactin gene: a target for tissue-specific and hormone-dependent transcription factors. Mol. Cell. Endocrinol. 100 (1994) 133-142
12. Dasen J.S., and Rosenfeld M.G. Signaling and transcriptional mechanisms in pituitary development. Annu. Rev. Neurosci. 24 (2001) 327-355
13. Lopez-Fernandez J., et al. Differentiation of lactotrope precursor GHFT cells in response to fibroblast growth factor-2. J. Biol. Chem. 275 (2000) 21653-21660
14. Schweppe, R. et al. Functional components of fibroblast growth factor signal transduction in pituitary cells. J. Biol. Chem. 272, 30852-30859
15. Shimon I., et al. Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. J. Clin. Invest. 97 (1996) 187-195
16. Yu S., et al. Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. Mol. Endocrinol. 16 (2002) 1069-1078
17. Tentler J.J., et al. Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells. Endocrine 20 (2003) 3-12
18. Schweppe R.E., et al. Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter. J. Biol. Chem. 278 (2003) 16863-16872
19. Bradford A.P., et al. GHF-1/Pit-1 functions as a cell-specific integrator of Ras signaling by targeting the Ras pathway to a composite Ets-1/GHF-1 response element. J. Biol. Chem. 271 (1996) 24639-24648
20. Augustijn K.D., et al. Structural characterization of the Pit-1-Ets-1 interactions: phosphorylation regulates Pit-1/Ets-1 binding. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12657-12662
21. Duval D.L., et al. Differential utilization of transcription activation subdomains by distinct coactivators regulates Pit-1 basal and Ras responsiveness. Mol. Endocrinol. 21 (2007) 172-185
22. Coletta R.D., et al. Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. J. Mammary. Gland Biol. Neoplasia. 9 (2004) 39-53
23. Shepherd T., and Hassell J. Role of Ets transcription factors in mammary gland development and oncogenesis. J. Mammary Gland Biol. Neoplasia 6 (2001) 129-140
24. Kurpios N.A., et al. Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J. Mammary Gland Biol. Neoplasia 8 (2003) 177-190
25. Harris J., et al. Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol. Endocrinol. 20 (2006) 1177-1187
26. Zhou J., et al. Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO J. 24 (2005) 635-644
27. Sapi E., et al. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res. 58 (1998) 1027-1033
28. Delannoy-Courdent A., et al. The expression of Ets-1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. J. Cell Sci. 111 (1998) 1521-1534
29. Neznanov N., et al. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res. 59 (1999) 4242-4246
30. Man A.K., et al. Ets2-dependent stromal regulation of mouse mammary tumors. Mol. Cell. Biol. 23 (2003) 8614-8625
31. Tynan J.A., et al. Ets2-dependent microenvironmental support of mouse mammary tumors. Oncogene 24 (2005) 6870-6876
32. Ghadersohi A., et al. Prostate-derived Ets transcription factor (PDEF) down regulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res. Treat. 102 (2007) 19-30
33. Xing X., et al. The Ets protein PEA3 suppresses Her-2/neu overexpression and inhibits tumorigenesis. Nat. Med. 6 (2000) 189-195
34. Yu Z., et al. Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol. Carcinog. 45 (2006) 667-675
35. Feldman R.J., et al. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res. 63 (2003) 4626-4631
36. Eckel K.L., et al. The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol. 22 (2003) 79-94
37. Schedin P.J., et al. ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene 23 (2004) 1766-1779
38. Witt A.E., et al. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J. Proteome Res. 5 (2006) 599-610
39. Tomlins S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
40. Chen C., et al. ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature 436 (2005) 1030-1034
41. Bergthorsson J.T., et al. A genome-wide study of allelic imbalance in human testicular germ cell tumors using microsatellite markers. Cancer Genet. Cytogenet. 164 (2006) 1-9
42. Adam M., et al. Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur. Urol. 44 (2003) 329-336
43. Gashaw I., et al. Gene signatures of testicular seminoma with emphasis on expression of ets variant gene 4. Cell. Mol. Life Sci. 62 (2005) 2359-2368
44. Fujimoto J., et al. Expression of ETS-1 related to angiogenesis in uterine endometrium during the menstrual cycle. J. Biomed. Sci. 10 (2003) 320-327
45. Koo T.B., et al. Differential expression of the PEA3 subfamily of ETS transcription factors in the mouse ovary and peri-implantation uterus. Reproduction 129 (2005) 651-657
46. Brar A.K., et al. An Ets motif in the proximal decidual prolactin promoter is essential for basal gene expression. J. Mol. Endocrinol. 29 (2002) 99-112
47. Yamamoto H., et al. Defective trophoblast function in mice with a targeted mutation of Ets2. Genes Dev. 12 (1998) 1315-1326
48. Georgiades P., and Rossant J. Ets2 is necessary in trophoblast for normal embryonic anteroposterior axis development. Development 133 (2006) 1059-1068
49. Donnison M., et al. Loss of the extraembryonic ectoderm in Elf5 mutants leads to defects in embryonic patterning. Development 132 (2005) 2299-2308
50. Fujimoto J., et al. Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Ann. Oncol. 13 (2002) 1598-1604
51. Simpson S., et al. Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines. Oncogene 14 (1997) 2149-2157
52. Lai H.C., et al. Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol. Oncol. 96 (2005) 314-319
53. Nishioka Y., et al. A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett. 200 (2003) 49-55
54. van Riggelen J., et al. Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells. J. Biol. Chem. 280 (2005) 3286-3294
55. Iwasaki M., et al. E1AF/PEA3 reduces the invasiveness of SiHa cervical cancer cells by activating serine proteinase inhibitor squamous cell carcinoma antigen. Exp. Cell Res. 299 (2004) 525-532
56. Fujimoto J., et al. Sex steroid-dependent angiogenesis in uterine endometrial cancers. J. Steroid Biochem. Mol. Biol. 93 (2005) 161-165
57. Takai N., et al. Clinical relevance of Elf-1 overexpression in endometrial carcinoma. Gynecol. Oncol. 89 (2003) 408-413
58. Planaguma J., et al. Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma. J. Pathol. 207 (2005) 422-429
59. Saito T., et al. Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells. Cancer Lett. 209 (2004) 237-243
60. Mizumoto H., et al. Acceleration of invasive activity via matrix metalloproteinases by transfection of the estrogen receptor-alpha gene in endometrial carcinoma cells. Int. J. Cancer 100 (2002) 401-406
61. Fujimoto J., et al. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 66 (2004) 420-428
62. Takai N., et al. The significance of Elf-1 expression in epithelial ovarian carcinoma. Int. J. Mol. Med. 12 (2003) 349-354
63. Wilson L.A., et al. Role of the transcription factor Ets-1 in cisplatin resistance. Mol. Cancer Ther. 3 (2004) 823-832
64. Behrens P., et al. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J. Pathol. 194 (2001) 43-50
65. Davidson B., et al. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?. Cancer Metastasis Rev. 22 (2003) 103-115
66. Hung M.C., and Wang S.C. Suppressing HER2/neu-mediated cell transformation by transcriptional repressors. Breast Dis. 11 (2000) 133-144
67. Fuhrer D., et al. Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours. Eur. J. Endocrinol. 152 (2005) 785-790
68. de Nigris F., et al. Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Res. 61 (2001) 2267-2275
69. Fauquette V., et al. The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. Biochem. J. 386 (2005) 35-45
70. Ito Y., et al. Ets-2 overexpression contributes to progression of pancreatic adenocarcinoma. Oncol. Rep. 9 (2002) 853-857
71. Richard V., et al. PTHrP gene expression in cancer: do all paths lead to Ets?. Crit. Rev. Eukaryot. Gene Expr. 15 (2005) 115-132